Global Drug-Eluting Bioabsorbable Stents Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

Global Drug-Eluting Bioabsorbable Stents Market, By Material

The Global Drug-Eluting Bioabsorbable Stents Market has been segmented by Material into Metallic based drug eluting stents and Polymer based drug eluting stents.

Metallic-based drug-eluting stents, historically prevalent in the market, are typically composed of materials like stainless steel or cobalt-chromium alloy. These stents are known for their durability and mechanical strength, providing robust support to diseased arteries while delivering therapeutic drugs to prevent restenosis. Concerns have arisen regarding the long-term presence of metal in the body and the potential for adverse reactions, leading to the emergence of alternative materials like polymers.

Polymer-based drug-eluting stents represent a newer generation of stent technology designed to address limitations associated with metallic stents. These stents utilize biocompatible polymers that gradually degrade over time, allowing the stent to be absorbed by the body once it has served its purpose. This bioabsorbable property eliminates the long-term presence of a foreign material in the artery, reducing the risk of late complications such as thrombosis and inflammation. Polymer-based stents offer flexibility in drug delivery profiles and may allow for more tailored treatment approaches. While still undergoing refinement and clinical evaluation, polymer-based drug-eluting stents hold promise for improving patient outcomes and reducing the need for long-term antiplatelet therapy.

Global Drug-Eluting Bioabsorbable Stents Market, By Stents

The Global Drug-Eluting Bioabsorbable Stents Market has been segmented by Stents into Coronary Artery Stents, Peripheral Artery Stents, and Non-vascular Stents.

Coronary artery stents represent the largest segment of the market, driven by the high prevalence of coronary artery disease (CAD) and the increasing preference for minimally invasive treatments. Drug-eluting bioabsorbable stents are increasingly used in coronary interventions because they not only provide mechanical support to the coronary arteries but also release drugs to prevent restenosis (re-narrowing of arteries). These stents gradually absorb into the body, which eliminates the need for long-term foreign material presence, making them particularly attractive for long-term cardiovascular health.

Peripheral artery stents are another important segment, although smaller than coronary artery stents. These stents are used to treat peripheral artery disease (PAD), a condition where the peripheral arteries, often in the legs, become narrowed or blocked due to atherosclerosis. Bioabsorbable drug-eluting stents for peripheral arteries offer the advantage of providing temporary support while delivering therapeutic drugs to prevent restenosis. While this segment is growing, it faces challenges such as the more complex vascular anatomy of peripheral arteries and higher procedural risks. However, with increasing rates of PAD and the global aging population, this segment is expected to see growth in demand for bioabsorbable stents that offer better patient outcomes.

The non-vascular stents category is a smaller but emerging segment in the drug-eluting bioabsorbable stents market. These stents are used in applications outside the traditional vascular systems, such as in the biliary ducts, esophagus, and gastrointestinal tract. Non-vascular stents are primarily used to treat conditions such as cancer, where stents are inserted to help maintain the patency of blocked ducts or passages. Bioabsorbable stents in these non-vascular applications offer the advantage of temporary support and eliminate the need for permanent implantation. As medical technology advances and more clinical trials support their effectiveness, the market for non-vascular drug-eluting bioabsorbable stents is expected to expand, especially in the treatment of obstructive conditions in various organ systems.

Global Drug-Eluting Bioabsorbable Stents Market, By Application

The Global Drug-Eluting Bioabsorbable Stents Market has been segmented by Application into Coronary artery diseases and Peripheral artery diseases.

Within the realm of coronary artery diseases, drug-eluting bioabsorbable stents (DES-BRS) have emerged as a groundbreaking solution for the treatment of coronary artery lesions. These stents, coated with drugs to prevent restenosis and promote healing, offer significant advantages over traditional metallic stents. By gradually dissolving over time, they reduce the risk of long-term complications such as in-stent restenosis and thrombosis, while also restoring vessel flexibility and function. This makes DES-BRS particularly suitable for patients with CAD, providing effective revascularization and improving long-term outcomes compared to bare-metal or drug-eluting metallic stents.

In the realm of peripheral artery diseases, the application of drug-eluting bioabsorbable stents represents a promising frontier in endovascular interventions. Peripheral artery diseases encompass a range of vascular conditions affecting arteries outside the heart and brain, typically involving the lower extremities. These conditions can lead to significant morbidity and impaired quality of life, often necessitating interventions such as angioplasty and stenting to restore blood flow and alleviate symptoms. Drug-eluting bioabsorbable stents offer several advantages in this context, including reduced risk of stent fractures, improved vessel healing, and the potential for future interventions without the constraints imposed by permanent metallic implants. By catering to the unique anatomical and physiological challenges of peripheral artery diseases, DES-BRS holds the potential to revolutionize the management of these conditions, offering patients a safer and more effective alternative to conventional stenting techniques.

Drivers

• Increasing heart disease cases globally
• Better bioabsorbable stent technology
• Demand for less invasive treatments

• Need for safer stents - The imperative for safer stents underscores a critical aspect of medical device innovation, particularly in the context of cardiovascular care. With cardiovascular diseases remaining a leading cause of mortality worldwide, the development of stents that prioritize patient safety is paramount. Safer stents aim to mitigate the risk of complications such as stent thrombosis, restenosis, and endothelial dysfunction, which can have severe consequences for patients.
  
  By incorporating advanced materials, innovative coatings, and improved drug delivery mechanisms, manufacturers strive to enhance the biocompatibility and hemocompatibility of stents, reducing the likelihood of adverse events and improving patient outcomes. Regulatory bodies play a crucial role in ensuring the safety and efficacy of stents through rigorous evaluation processes and post-market surveillance, fostering trust among healthcare professionals and patients alike in the pursuit of safer interventions.

Restraints

• Concerns about long-term effectiveness
• Limited proof of superiority over traditional stents

• Challenges in consistent stent performance - Challenges in ensuring consistent stent performance pose significant hurdles for medical device developers and healthcare providers seeking to deliver optimal patient care. Consistency in stent performance is essential to ensure predictable outcomes and long-term effectiveness in treating coronary artery disease and other cardiovascular conditions. Variability in factors such as stent deployment, apposition, and drug elution kinetics can impact clinical efficacy and safety, leading to suboptimal treatment results and potential complications.
  
  Addressing these challenges requires a comprehensive approach that encompasses advanced engineering techniques, robust quality control measures, and rigorous clinical validation. By optimizing stent design, manufacturing processes, and deployment protocols, stakeholders can mitigate variability and enhance the reliability and predictability of stent performance, ultimately improving patient care and clinical outcomes.

Opportunities

• Using in more conditions like peripheral artery disease
• Improving stent durability and drug delivery
• Improving post-market surveillance

• Considering patient feedback in design - Considering patient feedback in the design of medical devices, particularly stents, is integral to developing solutions that meet the evolving needs and preferences of end-users. Patients play a crucial role in providing insights into their experiences, preferences, and priorities, which can inform product design, usability, and functionality. By engaging patients throughout the design process, manufacturers can gain valuable perspectives on factors such as device comfort, ease of use, and impact on quality of life, thereby enhancing patient satisfaction and adherence to treatment regimens.
  
  Patient-centered design approaches contribute to the development of more intuitive and user-friendly devices, reducing the burden on healthcare professionals and improving overall treatment experiences. Incorporating patient feedback in stent design fosters a collaborative and patient-centric approach to innovation, driving improvements in clinical outcomes and patient care.